Stratos Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$302K Buy
391
+25
+7% +$19.1K ﹤0.01% 1317
2025
Q4
$283K Buy
+366
New +$249K ﹤0.01% 1324
2025
Q2
Sell
-506
Closed -$321K 1469
2025
Q1
$321K Sell
506
-115
-19% -$79.1K ﹤0.01% 1059
2024
Q4
$442K Sell
621
-158
-20% -$133K 0.01% 990
2024
Q3
$819K Buy
779
+108
+16% +$120K 0.01% 756
2024
Q2
$705K Buy
671
+46
+7% +$44.6K 0.01% 776
2024
Q1
$602K Buy
625
+202
+48% +$192K 0.01% 828
2023
Q4
$372K Sell
423
-43
-9% -$35.4K 0.01% 989
2023
Q3
$383K Buy
466
+106
+29% +$83.3K 0.01% 919
2023
Q2
$259K Buy
360
+43
+14% +$33.2K 0.01% 1010
2023
Q1
$260K Buy
317
+36
+13% +$27.2K 0.01% 932
2022
Q4
$203K Sell
281
-13
-4% -$9.59K 0.01% 1044
2022
Q3
$203K Buy
+294
New +$185K 0.01% 1018
2022
Q2
Sell
-535
Closed -$374K 1285
2022
Q1
$374K Buy
535
+16
+3% +$10.1K 0.01% 913
2021
Q4
$328K Sell
519
-231
-31% -$142K 0.01% 970
2021
Q3
$454K Buy
+750
New +$466K 0.01% 784
2020
Q3
Sell
-610
Closed -$380K 1052
2020
Q2
$380K Buy
+610
New +$346K 0.01% 693
2018
Q4
Sell
-31
Closed -$13K 2121
2018
Q3
$13K Buy
+31
New +$11.8K ﹤0.01% 2066
2018
Q2
Sell
-17
Closed -$6K 2214
2018
Q1
$6K Sell
17
-11
-39% -$3.83K ﹤0.01% 2554
2017
Q4
$11K Buy
+28
New +$11.3K ﹤0.01% 2129
2017
Q3
Sell
-1,051
Closed -$516K 954
2017
Q2
$516K Sell
1,051
-1
-0.1% -$438 0.03% 443
2017
Q1
$408K Buy
+1,052
New +$390K 0.02% 480

Other funds holding REGN

Stratos Wealth Partners's REGN Position: Q1 2026 in Review

Stratos Wealth Partners increased its Regeneron Pharmaceuticals (REGN) stake by 6.8% in Q1 2026, buying an estimated $19.1K and bringing the position to 391 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #1317.

Stratos Wealth Partners first reported a position in REGN in Q1 2017 and has held it in 22 quarters since. The position peaked at $819K in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Stratos Wealth Partners held 391 shares of Regeneron Pharmaceuticals worth $302K as of Q1 2026.
  • Stratos Wealth Partners bought 25 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $19.1K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q1 2026, its #1317 holding.
  • Stratos Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q1 2017 and has held it in 22 quarters since.
  • Stratos Wealth Partners's Regeneron Pharmaceuticals position peaked at $819K in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.